Semaglutide (the active ingredient in Ozempic® and Wegovy®) works as an agonist on only the GLP-1 (Glucagon-like Peptide-1) receptor, leading to increased insulin release, reduced glucagon secretion, slowed gastric emptying, and increased feelings of fullness, and it...
View Product
Dual GLP-1 and GIP action
Distinct dual incretin mechanism
Targets two metabolic pathways
Tirzepatide has a dual mechanism of action through the GLP-1 and GIP receptor agonist. Its dual action makes it distinct from medications like semaglutide, which primarily target the GLP-1 receptor alone. GLP-1 Injections (Semaglutide & Tirzepatide)...
View Product
Supports healthy blood sugar control
Once-weekly GLP-1 receptor support
Promotes feelings of fullness
Semaglutide (the active ingredient in Ozempic® and Wegovy®) works as an agonist on only the GLP-1 (Glucagon-like Peptide-1) receptor, leading to increased insulin release, reduced glucagon secretion, slowed gastric emptying, and increased feelings of fullness,...
View Product
